← Back to headlines
Gilead Sciences Q2 Sales Boosted by HIV and Oncology Growth
Gilead Sciences reported a 10% jump in Q2 base sales, driven by strong growth in its HIV and oncology segments, despite a decline in Veklury sales.
Sources
Showing 0 of 1 sources
No articles available in your preferred languages.
1 article available in other languages below.
Related Stories
Mark Zuckerberg's Superyacht Accused of Refusing Aid to Distressed Boat
17m ago
Used Car Listings on Index Oglasi Feature Various Models
21m ago
Dacia Hipster Electric Model Nears Production with Leaked Patent Designs
22m ago
Hungarian Twenty-Somethings Save Nearly One Million Forints Annually, K&H Survey Finds
23m ago